Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie's 4Q Revenues up 4% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbvie’s 4Q Revenues up 4%

Humira sales were down 37% in the quarter. Skyrizi sales were $3.2 billion, up 51%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbvie
3Q Revenues: $14.5 billion (+4%)
3Q Earnings: $1.6 billion (-12%)
YTD Revenues: $41.2 billion (+3%) 
YTD Earnings: $4.3 billion (+6%)
Comments: Humira sales were $2.2 billion, down 37% in the quarter. Skyrizi sales were $3.2 billion, an increase of 51%. Rinvoq revenues were $1.6 billion, up 45%. Imbruvica sales were $828 million, down 9%. Venclexta sales were $677 million, up 15%.Elahere sales were $139 million. Botox Therapeutic sales were $848 million, up 13%. Vraylar revenues were $875 million, an increase of 17%. Ubrelvy sales were $269 million, an increase of 15%, and Qulipta sales were $176 million, up 34%. Botox Cosmetic revenues were $671 million, up 8%. Juvederm sales were down 20% to $258 million. Abbvie recently completed its acquisition of Cerevel, adding a pipeline of complementary assets to its neuroscience portfolio.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters